Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.44 |
| ▸ | MME | P08473 | 3/20 | 0.36 |
| ▸ | QRFPR | Q96P65 | 2/20 | 0.34 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.33 |
| ▸ | CPB1 | P15086 | 1/20 | 0.32 |
| ▸ | NMT2 | O60551 | 1/20 | 0.32 |
| ▸ | NMT1 | P30419 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29451161 | 0.99 | SLC15A2 (0.46) | SLC15A2MMEQRFPRCPB2ITGB3 | |
| SCHEMBL29435919 | 0.96 | SLC15A2 (0.46) | SLC15A2MMEQRFPRCPB2CPB1 | |
| SCHEMBL20783813 | 0.94 | SLC15A2 (0.49) | SLC15A2MMECPB2ITGB3ITGA2B | |
| SCHEMBL31453803 | 0.94 | SLC15A2 (0.49) | SLC15A2MMECPB2ITGB3ITGA2B | |
| SCHEMBL29590566 | 0.94 | SLC15A2 (0.49) | SLC15A2MMECPB2ITGB3ITGA2B | |
| SCHEMBL29591824 | 0.93 | SLC15A2 (0.42) | SLC15A2MMEQRFPRNMT2NMT1 | |
| SCHEMBL483799 | 0.91 | SLC15A2 (0.42) | SLC15A2CPB2ITGB3ITGA2BCPB1 | |
| SCHEMBL1666820 | 0.91 | SLC15A2 (0.42) | SLC15A2CPB2ITGB3ITGA2BCPB1 | |
| Hydrochloric Acid SCHEMBL1436163 | 0.90 | SLC15A2 (0.41) | SLC15A2CPB2ITGB3ITGA2BCPB1 | |
| Hydrochloric Acid SCHEMBL2199717 | 0.90 | SLC15A2 (0.41) | SLC15A2CPB2ITGB3ITGA2BCPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340591-A1 | COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE CONTAINING NOVEL COMPOUND | ANYGEN CO LTD (KR) | 2025-11-06 | — | — | US | claimed |
| CN-117616034-A | Composition for preventing or treating inflammatory bowel disease containing novel compounds | 安尼根有限公司 | 2024-02-27 | — | — | CN | claimed |
| EP-4317171-A1 | COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE CONTAINING NOVEL COMPOUND | Anygen Co., Ltd. (KR) | 2024-02-07 | — | — | EP | claimed |
| US-20230212222-A1 | COMPOSITION FOR ANTI-DIABETES AND ANTI-OBESITY COMPRISING NOVEL COMPOUND | ANYGEN CO., LTD. (KR) | 2023-07-06 | — | — | US | claimed |
| WO-2023038464-A1 | COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE CONTAINING NOVEL COMPOUND | 애니젠 주식회사 | 2023-03-16 | — | — | WO | claimed |
| EP-4119570-A1 | COMPOSITION FOR ANTI-DIABETES AND ANTI-OBESITY COMPRISING NOVEL COMPOUND | Anygen Co., Ltd. (KR) | 2023-01-18 | — | — | EP | claimed |
| CN-115362165-A | Antidiabetic and antiobesity composition comprising novel compounds | 安尼根有限公司 | 2022-11-18 | — | — | CN | claimed |
| US-20250340591-A1 | COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE CONTAINING NOVEL COMPOUND | ANYGEN CO LTD (KR) | 2025-11-06 | — | — | US | disclosed |
| US-20240174999-A1 | ARCHAEAL PEPTIDE RECOMBINASE ? A NOVEL PEPTIDE LIGATING ENZYME | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2024-05-30 | — | — | US | disclosed |
| CN-117616034-A | Composition for preventing or treating inflammatory bowel disease containing novel compounds | 安尼根有限公司 | 2024-02-27 | — | — | CN | disclosed |
| EP-4317171-A1 | COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE CONTAINING NOVEL COMPOUND | Anygen Co., Ltd. (KR) | 2024-02-07 | — | — | EP | disclosed |
| US-20230212222-A1 | COMPOSITION FOR ANTI-DIABETES AND ANTI-OBESITY COMPRISING NOVEL COMPOUND | ANYGEN CO., LTD. (KR) | 2023-07-06 | — | — | US | disclosed |
| WO-2023038464-A1 | COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE CONTAINING NOVEL COMPOUND | 애니젠 주식회사 | 2023-03-16 | — | — | WO | disclosed |
| EP-4119570-A1 | COMPOSITION FOR ANTI-DIABETES AND ANTI-OBESITY COMPRISING NOVEL COMPOUND | Anygen Co., Ltd. (KR) | 2023-01-18 | — | — | EP | disclosed |
| CN-115362165-A | Antidiabetic and antiobesity composition comprising novel compounds | 安尼根有限公司 | 2022-11-18 | — | — | CN | disclosed |
| EP-4061830-A1 | ARCHAEAL PEPTIDE RECOMBINASE - A NOVEL PEPTIDE LIGATING ENZYME | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340591-A1 | COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE CONTAINING NOVEL COMPOUND | GPR39, FABP2, GPR119 | SLC15A2 452/4885MME 4394/4885QRFPR 895/4885 |
| US-20230212222-A1 | COMPOSITION FOR ANTI-DIABETES AND ANTI-OBESITY COMPRISING NOVEL COMPOUND | GPR119, GPR39, FABP4 | SLC15A2 902/4885MME 2237/4885QRFPR 964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.